Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Trial Profile

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NATURE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
    • 22 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment due to loss of funding support.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top